April 2017

Synexus, Radiant Research to integrate operations

Thursday, April 27, 2017

European-headquartered Synexus and U.S.-based Radiant Research announced a full operational integration to form a single global site network of 185 sites with 1,500 employees. This move will create the world’s largest site network, spanning 11 countries and offering access to more than 100 million patients in key clinical development markets, operating under the Synexus name.

[Read More]

AstraZeneca tops out new global R&D center and HQ in Cambridge, UK

Wednesday, April 26, 2017

AstraZeneca marks a key milestone in its successful move to Cambridge, U.K., with the “topping out” of its new, state-of-the-art, strategic R&D center and global corporate headquarters at the heart of the Cambridge Biomedical Campus (CBC). The company, including its biologics research and development arm, MedImmune, already has 2,000 employees actively engaged in the city’s vibrant scientific, academic, clinical and business community. Occupation of the site will begin in stages in 2018.

[Read More]

Kalytera identifies sites for planned GvHD clinical trials

Wednesday, April 26, 2017

Kalytera Therapeutics, a clinical-stage biopharmaceutical company developing next-generation cannabinoid- derived therapeutics, has developed the multicenter location component of the plan for the proposed clinical trials to evaluate cannabidiol (CBD) for the prevention and treatment of Graft versus Host Disease (GvHD). Kalytera is developing this clinical trial plan with the intent of obtaining FDA and EMEA approval for commercialization.

[Read More]